Adma Biologics Inc (NASDAQ: ADMA) has a higher price-to-earnings ratio of 61.17x compared to its average ratio. ADMA has 36-month beta value of 0.60. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADMA is 228.50M, and currently, short sellers hold a 5.92% ratio of that float. The average trading volume of ADMA on February 05, 2025 was 2.80M shares.
ADMA) stock’s latest price update
Adma Biologics Inc (NASDAQ: ADMA)’s stock price has plunge by 2.61relation to previous closing price of 16.47. Nevertheless, the company has seen a 4.51% surge in its stock price over the last five trading sessions. zacks.com reported 2025-02-03 that Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.98% move from its prior day’s close.
ADMA’s Market Performance
ADMA’s stock has risen by 4.51% in the past week, with a monthly drop of -5.95% and a quarterly rise of 3.62%. The volatility ratio for the week is 4.42% while the volatility levels for the last 30 days are 4.78% for Adma Biologics Inc The simple moving average for the past 20 days is 0.49% for ADMA’s stock, with a 11.93% simple moving average for the past 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at -7.28% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.51% of loss for the given period.
Volatility was left at 4.78%, however, over the last 30 days, the volatility rate increased by 4.42%, as shares sank -8.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.08% lower at present.
During the last 5 trading sessions, ADMA rose by +4.51%, which changed the moving average for the period of 200-days by +179.80% in comparison to the 20-day moving average, which settled at $16.82. In addition, Adma Biologics Inc saw -1.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Tade Brad L., who sale 15,000 shares at the price of $21.15 back on Nov 22 ’24. After this action, Tade Brad L. now owns 199,433 shares of Adma Biologics Inc, valued at $317,250 using the latest closing price.
Grossman Adam S, the President and CEO of Adma Biologics Inc, sale 48,967 shares at $21.10 during a trade that took place back on Nov 22 ’24, which means that Grossman Adam S is holding 1,989,007 shares at $1,033,204 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.3 for the present operating margin
- 0.49 for the gross margin
The net margin for Adma Biologics Inc stands at 0.18. The total capital return value is set at 0.33. Equity return is now at value 35.55, with 18.42 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at 0.77. The debt to equity ratio resting at 0.48. The interest coverage ratio of the stock is 6.65.
Currently, EBITDA for the company is 5.12 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 10.5. The receivables turnover for the company is 7.63for trailing twelve months and the total asset turnover is 0.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.09.
Conclusion
To put it simply, Adma Biologics Inc (ADMA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.